| abstract |
FIELD: medicine.SUBSTANCE: invention relates to a compound of the formula (I) or its pharmaceutically acceptable salt, having inhibitory activity against LSD1, an LSD1inhibitor, a pharmaceutical composition and an antitumor agent based on them, a method for the treatment of a patient with acute human myelocytic leukemia and small cell lung cancer, as well as their use in the production of such an antitumor agent. In the general formula (I), ring A is a 5-9-element monocyclic, bridged cyclic or spirocyclic nitrogen-containing saturated heterocyclic group optionally additionally containing 1 nitrogen atom, ring B is phenyl or 9-element bicyclic aromatic heterocyclic group with 1-3 nitrogen atoms, R1 is nitro or cyano, R2 is halogen, R3 is unsubstituted amino, mono- or di(C1-C6 alkyl)amino, (C3-C7 cycloalkyl)amino or C1-C6 alkyl, R4 is halogen, unsubstituted C3-C7 cycloalkyl or C1-C8 alkyl, unsubstituted or substituted OH or cyclobutyl, R5 is hydrogen or C1-C6 alkyl, R6 is hydrogen, l is an integer from 0 to 1, m is an integer from 0 to 2, and n is an integer from 0 to 3, where if m is 2, two R3 can be the same or different, and if n is from 2 to 3, from two to three R4 can be the same or different.EFFECT: provision of compounds of the formula (I) or their pharmaceutically acceptable salts with inhibitory activity against LSD1.12 cl, 42 tbl, 300 ex |